A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy
PI3K/Akt/mTOR pathway
ROS-reactive oxygen species
epigallocatechin gallate (EGCG)
glioma
metformin
molecular docking
quantum mechanics (QM)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
11
2022
accepted:
02
03
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
Glioma is the most devastating high-grade tumor of the central nervous system, with dismal prognosis. Existing treatment modality does not provide substantial benefit to patients and demands novel strategies. One of the first-line treatments for glioma, temozolomide, provides marginal benefit to glioma patients. Repurposing of existing non-cancer drugs to treat oncology patients is gaining momentum in recent years. In this study, we investigated the therapeutic benefits of combining three repurposed drugs, namely, metformin (anti-diabetic) and epigallocatechin gallate (green tea-derived antioxidant) together with temozolomide in a glioma-induced xenograft rat model. Our triple-drug combination therapy significantly inhibited tumor growth
Identifiants
pubmed: 37025487
doi: 10.3389/fphar.2023.1096614
pii: 1096614
pmc: PMC10070706
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1096614Informations de copyright
Copyright © 2023 Kuduvalli, Daisy, Vaithy, Purushothaman, Ramachandran Muralidharan, Agiesh, Mezger, Antony, Subramani, Dubashi, Biswas, Guruprasad and Anitha.
Déclaration de conflit d'intérêts
The authors declare that the current research work is exclusively licensed to ScirosBio (FZC), Sharjah Research Technology and Innovation (SRTI) Park, PO Box 70752, Sharjah, United Arab Emirates. ScirosBio is a UAE based, Bio-Pharmaceutical startup, engaged in research, development and commercialization of biopharmaceutical drugs majorly related to various disease indications including oncology, neurological disorders, and diabetes.
Références
Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
J Vis Exp. 2013 Jan 19;(71):
pubmed: 23380713
Cancer Med. 2019 May;8(5):2252-2267
pubmed: 30929309
Front Pharmacol. 2018 Mar 16;9:218
pubmed: 29615902
Cell Death Differ. 2017 May;24(5):878-888
pubmed: 28362427
Ann Intern Med. 2006 Mar 7;144(5):337-43
pubmed: 16520474
Free Radic Biol Med. 2016 Jan;90:91-100
pubmed: 26577174
Cancer Invest. 2012 Jan;30(1):48-56
pubmed: 22236189
Sci Rep. 2014 Nov 10;4:6948
pubmed: 25382104
Antioxidants (Basel). 2020 Jul 29;9(8):
pubmed: 32751256
Int J Mol Sci. 2021 May 05;22(9):
pubmed: 34063168
Mol Cancer Ther. 2007 Sep;6(9):2544-53
pubmed: 17876051
J Biol Chem. 2010 Dec 24;285(52):40461-71
pubmed: 20880848
Cancer Drug Resist. 2021;4:17-43
pubmed: 34337348
Cancers (Basel). 2020 Jan 15;12(1):
pubmed: 31952173
Int J Biol Sci. 2017 Nov 27;13(12):1560-1569
pubmed: 29230104
Front Mol Biosci. 2021 Jan 27;7:620677
pubmed: 33585565
Oncogene. 2007 Jan 11;26(2):186-97
pubmed: 16819506
NPJ Syst Biol Appl. 2020 Jun 2;6(1):16
pubmed: 32487991
Molecules. 2020 Jan 22;25(3):
pubmed: 31979082
Oncotarget. 2017 Dec 6;8(68):113090-113104
pubmed: 29348889
Int J Mol Sci. 2019 Jan 09;20(2):
pubmed: 30634433
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
Oncol Rep. 2017 Feb;37(2):657-670
pubmed: 27959421
Stem Cells Transl Med. 2012 Nov;1(11):811-24
pubmed: 23197693
Int J Mol Sci. 2016 Jun 22;17(6):
pubmed: 27338365
Tumour Biol. 2019 Jan;41(1):1010428318815413
pubmed: 30803422
Life Sci. 2022 Jul 15;301:120609
pubmed: 35526592
Front Pharmacol. 2021 Mar 15;12:628690
pubmed: 33790792
Biochem Pharmacol. 2022 May;199:114981
pubmed: 35227644
PLoS One. 2014 May 06;9(5):e96801
pubmed: 24802416
Clin Cancer Res. 2013 May 15;19(10):2699-709
pubmed: 23536437
J Biomed Inform. 2016 Dec;64:131-138
pubmed: 27697594
J Biomol Struct Dyn. 2021 Aug;39(13):4582-4593
pubmed: 32567979
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Curr Mol Pharmacol. 2022;15(2):338-360
pubmed: 33881978
Molecules. 2020 Jul 09;25(14):
pubmed: 32660101
Int J Cancer. 2019 Jan 15;144(2):273-280
pubmed: 30091464
Cancer Res. 2014 Sep 1;74(17):4783-95
pubmed: 24994714
Cells. 2020 Apr 30;9(5):
pubmed: 32365809
Annu Rev Entomol. 1992;37:615-36
pubmed: 1311541
Front Oncol. 2020 Oct 02;10:572904
pubmed: 33123479
Cancers (Basel). 2020 Jul 05;12(7):
pubmed: 32635637
Nat Rev Cancer. 2015 May;15(5):302-10
pubmed: 25855404
Front Pharmacol. 2018 Oct 16;9:1162
pubmed: 30405405
Hippokratia. 2018 Jul-Sep;22(3):105-112
pubmed: 31641331
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Fish Physiol Biochem. 2010 Sep;36(3):687-697
pubmed: 19680766
PLoS One. 2013 Dec 23;8(12):e85022
pubmed: 24376860
Molecules. 2021 Mar 05;26(5):
pubmed: 33808001
Oncogenesis. 2017 Aug 14;6(8):e371
pubmed: 28805788
Acta Crystallogr D Biol Crystallogr. 2002 Jun;58(Pt 6 No 1):899-907
pubmed: 12037327
Front Oncol. 2019 Sep 26;9:963
pubmed: 31616641
Cancers (Basel). 2019 Mar 13;11(3):
pubmed: 30871240
Neuro Oncol. 2005 Apr;7(2):134-53
pubmed: 15831232
Mol Cancer. 2018 Feb 19;17(1):37
pubmed: 29455665
Daru. 2018 Dec;26(2):93-103
pubmed: 30242671
Cancer Cell Int. 2018 May 04;18:69
pubmed: 29755294
J Clin Invest. 2016 Oct 3;126(10):3699-3707
pubmed: 27571407
Biomed Res Int. 2018 Jan 31;2018:4010629
pubmed: 29651429
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Am J Surg Pathol. 2002 Jun;26(6):750-7
pubmed: 12023579
Brain Pathol. 2009 Jan;19(1):112-20
pubmed: 19076776
Front Cell Dev Biol. 2019 May 03;7:70
pubmed: 31131274
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992
pubmed: 27646922
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
Cancer Lett. 2011 Mar 28;302(2):100-8
pubmed: 21257259
Aging (Albany NY). 2020 Sep 14;12(17):17582-17600
pubmed: 32927432
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Anal Methods. 2014 May 7;6(9):3019-3024
pubmed: 24955137
BMC Cancer. 2018 Apr 3;18(1):379
pubmed: 29614990
Mol Neurobiol. 2020 May;57(5):2461-2478
pubmed: 32152825
Oxid Med Cell Longev. 2020 Aug 12;2020:9723686
pubmed: 32850004
Cell Death Differ. 2006 Sep;13(9):1423-33
pubmed: 16676004
Biomolecules. 2019 Dec 09;9(12):
pubmed: 31835318
PLoS One. 2015 Apr 13;10(4):e0123721
pubmed: 25867026
Front Oncol. 2021 May 03;11:664149
pubmed: 34012924
Oxid Med Cell Longev. 2021 Jun 24;2021:5546493
pubmed: 34257807
Front Oncol. 2018 May 15;8:160
pubmed: 29868481
Cancer Res. 2005 Jun 15;65(12):5248-55
pubmed: 15958570
Oxid Med Cell Longev. 2016;2016:6475624
pubmed: 26649142
Sci Rep. 2016 Jul 29;6:30630
pubmed: 27471070
Nutrients. 2012 Nov 08;4(11):1679-91
pubmed: 23201840
Oncotarget. 2016 May 31;7(22):33440-50
pubmed: 26967052
Oxid Med Cell Longev. 2020 Jun 15;2020:2534643
pubmed: 32617133
Medchemcomm. 2017 Apr 13;8(9):1742-1773
pubmed: 30108886
J Biol Chem. 2014 May 9;289(19):13476-91
pubmed: 24634221
Front Mol Neurosci. 2011 Dec 02;4:51
pubmed: 22144946
Antioxidants (Basel). 2021 Apr 22;10(5):
pubmed: 33922139
J Neurooncol. 2015 Jan;121(1):41-52
pubmed: 25173233